Sarepta adds muscular dystrophy gene therapies via Myonexus pact – FierceBiotech
FierceBiotech |
Sarepta adds muscular dystrophy gene therapies via Myonexus pact
FierceBiotech Sarepta is determined to stay at the forefront of genetic medicines for muscular dystrophies and to that end has signed another R&D deal—this time with Myonexus Therapeutics—and taken an option on buying the company. The $60 million upfront deal … Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene … Sarepta's eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug |
